BioGenex Precision Medicine systems aid Mohs micrographic surgery with rapid nineteen minute CK IHC protocol

08 May

The BioGenex i6000® automated staining system, antibodies, and reagents were used by researchers to develop an ultra-rapid cytokeratin (CK) immunostaining protocol for Mohs micrographic surgery (MMS) which otherwise uses a lengthy time-consuming protocol.

Mohs micrographic surgery is a well-established surgical procedure for removing Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). The technique often involves removing a thin layer of tissue one at a time and having the tissues H&E stained for marginal characteristics during the surgery rather than post-surgery. This ensures complete removal of the cancerous tissue with minimal noncancerous tissue loss to the patient. However, failure in detecting and differentiating the tumor cells from cancerous cells using H&E staining has led to a recurrence of tumors in about 1-2% in cases of BCC and 3.1% in SCC.


A team of researchers from the University of South Florida has chosen BioGenex products to develop a rapid protocol for frozen-section CK immunostaining of non-melanoma skin cancer (NMSK). CK immunostaining using pan-cytokeratin antibodies provides increased confidence in differentiating the epithelial and mesothelial cells from mesenchymal cells in normal and tumor tissues, especially for previously negative H&E tissues. NMSK show characteristics of over-expression of various classes of cytokeratins. The BioGenex AE1/AE3 – anti-CK antibody cocktail was chosen to target a full spectrum of keratin polypeptides, both acidic and basic to enhance the detection level. AE1 targets CK10, 14, 15, 16 and 19; AE3 targets CK1, 2, 3, 4, 5, 6 and 7. BioGenex’s citrate buffer was used along with heat-induced antigen retrieval method. This buffer has been proven to work with the most common and difficult-to-retrieve antigens and is compatible with most of BioGenex’s antibodies.

The frozen sections from 21 patients who underwent MMS were subjected to the ultra-rapid protocol using the BioGenex i6000® automated staining system. For all cases, samples were submitted for permanent (FFPE) CK staining and H&E staining. The rapid CK results were compared with permanent (FFPE) CK immunostaining which showed similar results, suggesting the accuracy of the ultra-rapid 19-minute protocol. The study results were published in the Dermatologic Surgery

About BioGenex Laboratories

BioGenex designs develop and commercialize fully-automated molecular pathology systems for cancer diagnosis, prognosis, personalized medicine, and life science research. Our fully-automated workstations are the most in-depth systems available globally. Our customer-focused approach, with excellent technical and customer support provides a unique and powerful service for pathology labs. Our spirit of innovation drives us to deliver cutting edge technology, years ahead of our competition, and the finest systems for Life Science research and diagnostics.


Latest News